Pure Global AI
NCT06149741Recruiting

Defunctioning Left-sided Colostomy in Low Anterior Resection for Rectal Cancer

Umeå UniversityClinicalTrials.govprocedure
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
Defunctioning left-sided loop colostomy
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Umeå University
Location
Umeå, Sweden
Timeline & enrollment
Phase
N/A
Start date
Nov 20, 2023
End date
Dec 31, 2025
Enrollment
20 participants
Primary outcome

Low anterior resection syndrome

Summary

This is prospective, multi centre study evaluating a novel type of defunctioning loop stoma
 after low anterior resection for rectal cancer. Patients will be operated with a complete
 splenic flexure mobilisation and total mesorectal excision. An anastomosis will be fashioned
 at the pelvic floor. This will leave a redundant colon which will be brought up and matured
 in the left iliac fossa. Patient bowel function and quality of life will be monitored at
 baseline and at one year postoperatively, when the stoma will typically have been reversed.
 We anticipate less issues with dehydration and kidney injury, associated with the main
 alternative loop ileostomy. About 20 patients will be included in this pilot study.

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06149741
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06149741 through Pure Global AI's free database. This phase not specified trial is sponsored by Umeå University and is currently Recruiting. The study focuses on Rectal Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.